Phathom Pharmaceuticals Inc (PHAT)
9.34
-0.11
(-1.16%)
USD |
NASDAQ |
Nov 22, 16:00
9.32
-0.02
(-0.21%)
After-Hours: 20:00
Phathom Pharmaceuticals Enterprise Value: 479.70M for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 479.70M |
| November 21, 2024 | 487.22M |
| November 20, 2024 | 437.99M |
| November 19, 2024 | 481.75M |
| November 18, 2024 | 448.93M |
| November 15, 2024 | 441.40M |
| November 14, 2024 | 462.60M |
| November 13, 2024 | 507.73M |
| November 12, 2024 | 492.00M |
| November 11, 2024 | 736.79M |
| November 08, 2024 | 993.89M |
| November 07, 2024 | 1.106B |
| November 06, 2024 | 1.072B |
| November 05, 2024 | 1.097B |
| November 04, 2024 | 1.136B |
| November 01, 2024 | 1.089B |
| October 31, 2024 | 1.013B |
| October 30, 2024 | 1.031B |
| October 29, 2024 | 1.022B |
| October 28, 2024 | 1.029B |
| October 25, 2024 | 937.65M |
| October 24, 2024 | 948.58M |
| October 23, 2024 | 956.78M |
| October 22, 2024 | 974.54M |
| October 21, 2024 | 901.44M |
| Date | Value |
|---|---|
| October 18, 2024 | 939.70M |
| October 17, 2024 | 950.63M |
| October 16, 2024 | 966.35M |
| October 15, 2024 | 911.00M |
| October 14, 2024 | 885.04M |
| October 11, 2024 | 872.06M |
| October 10, 2024 | 914.42M |
| October 09, 2024 | 917.15M |
| October 08, 2024 | 967.03M |
| October 07, 2024 | 941.07M |
| October 04, 2024 | 1.020B |
| October 03, 2024 | 1.081B |
| October 02, 2024 | 986.16M |
| October 01, 2024 | 1.001B |
| September 30, 2024 | 1.076B |
| September 27, 2024 | 1.095B |
| September 26, 2024 | 1.115B |
| September 25, 2024 | 1.103B |
| September 24, 2024 | 1.074B |
| September 23, 2024 | 1.111B |
| September 20, 2024 | 1.157B |
| September 19, 2024 | 1.177B |
| September 18, 2024 | 1.211B |
| September 17, 2024 | 1.161B |
| September 16, 2024 | 1.188B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
116.44M
Minimum
Feb 13 2024
1.230B
Maximum
Sep 12 2024
583.64M
Average
552.82M
Median
Jul 13 2020
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.608M |
| Palatin Technologies Inc | 16.38M |
| iBio Inc | 14.05M |
| Theriva Biologics Inc | -12.68M |
| Oragenics Inc | 2.314M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -85.58M |
| Revenue (Quarterly) | 16.35M |
| Total Expenses (Quarterly) | 87.15M |
| EPS Diluted (Quarterly) | -1.32 |
| Gross Profit Margin (Quarterly) | 85.59% |
| Profit Margin (Quarterly) | -523.3% |
| Earnings Yield | -61.56% |
| Normalized Earnings Yield | -61.56 |